B01 A genetically-engineered mouse model of *de novo* bone metastasis. Juan Arriaga, Columbia University Medical Center, New York, NY, United States.

B02 Neutrophils and Snail orchestrate the establishment of a pro-tumor microenvironment in lung adenocarcinoma. Etienne Meylan, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.

B03 Acinar cell expansion: A new step in pancreatic tumorigenesis. Patrick Neuhoefer, Stanford University, Stanford, CA, United States.

B04 Activating K-Ras*A146T* mutations induce Mapk-dependent hyperproliferation in the intestinal epithelium. Emily Poulin, Beth Israel Deaconess Medical Center, Boston, MA, United States.

B05 BRAF inhibition and cytokine therapy for melanoma: A novel rational combined approach. Gabriele Romano, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

B06 A SOX9+ bile duct progenitor as a cell of origin of hepatocellular carcinoma. Patrick Viatour, Children's Hospital of Philadelphia, Philadelphia, PA, United States.

B07 Role of lysyl hydroxylases in metastatic lung cancer. Yanan Yang, Mayo Clinic, Rochester, MN, United States.

B08 Pathological roles of Ddx3x in hepatocellular carcinoma development. Li-Ru You, National Yang-Ming University, Taipei, Taiwan.

B09 Loss of diphthamide biosynthesis enzyme *Dph1* causes ER stress and sensitizes the liver to chemically- and genetically-induced tumorigenesis. Yi-Ru Yu, National Yang-Ming University, Taipei, Taiwan.

B10 The polyploid state plays a tumor suppressive role in the liver. Shuyuan Zhang, UT Southwestern Medical Center, Dallas, TX, United States.

B11 Foxm1 mediates maintenance and progression of mouse lung tumor driven by oncogenic Kras. I-Ching Wang, National Tsing Hua University, Hsinchu, Taiwan.

B12 The importance of the RASA1/R-Ras/Rel-A signaling axis in melanoma tumorigenesis. Minjung Kim, Moffitt Cancer Center, Tampa, FL, United States.

B13 The prevention of lymphoproliferative lesions arising in patient-derived cancer xenografts by anti-graft-versus-host-disease agents. Tsuyoshi Chijiwa, Department of Emergency and Critical Care Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

B14 Extracellular matrix composition shapes the fate of oncogenic events. Mario Colombo, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.

B15 The effects of obesity on tumor microenvironment and immunotherapy efficacy. Stephanie Dudzinski, Vanderbilt University, Nashville, TN, United States.

B17 A dual in vivo and in silico system to model ectopic lymph node structure formation and anti-tumor immune response in the murine tumor microenvironment. Adam Mailloux, H. Lee Moffitt Cancer Center, Tampa, FL, United States.

B18 The carcinogen-induced NTCU model: A pre-clinical mouse model for lung cancer Interception. Sarah Mazzilli, Boston University School of Medicine, Boston, MA, United States.

B19, PR05 Lineage specifiers SOX2 and NKX2-1 inversely regulate lung tumor immune microenvironment. Trudy Oliver, University of Utah, Salt Lake City, UT, United States.

B20 Alteration of colonic mesenchyme amplifies the loss of heterogeneity and the oncogenic effects of tumor suppressor APC. Raphaëlle Servant, Université de Sherbrooke, Sherbrooke, Québec, Canada.


B22 Novel pancreatic cancer stem cell surface biomarkers (CD19+31+45+133+) as target for pancreatic cancer therapy. Jayanta Das, Florida International University, Miami, FL, United States.

B23 Identifying regulatory networks and screening for genetic drivers of the stem cell state in Msi2+ pancreatic cancer cells. Lesley Ferguson, University of California San Diego, La Jolla, CA, United States.

B24 Stem cell lineage infidelity drives wound repair and cancer. Yejing Ge, The Rockefeller University, New York, NY, United States.

B25 Pten haplo-deficiency drives liver tumor initiation and progression in the microRNA-122a null mice via expansion of periportal hepatocyte-like cells. Wei-Ling Tu, National Yang-Ming University, Taipei, Taiwan.

B26 Whole genome sequencing and transcriptomic analysis of MMTV-Neu and MMTV-PyMT mammary tumors. Eran Andrechek, Michigan State University, East Lansing, MI, United States.

B27 The use of mouse models for understanding the in vivo impact of cancer-relevant genetic defects on genomic instability induced by human LINE-1 retrotransposon. Victoria Belancio, Tulane University, New Orleans, LA, United States.

B28 Development of estrogen-dependent and estrogen receptor-negative cervical cancer in HPV transgenic mice. Sang-Hyuk Chung, University of Houston, Houston, TX, United States.
B29 A carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Damiano Fantini, Northwestern University, Chicago, IL, United States.

B30 An in silico spatio-structural mathematical model for plastic drug resistance in heterogeneous melanoma subpopulations. Arran Hodgkinson, Université de Montpellier, Montpellier, France.

B31, PR10 RNA sequencing based analysis of transposon-induced tumors reveals novel insights into disease pathogenesis. David Largaespada, University of Minnesota, Minneapolis, MN, United States.

B32 Targeting WNT signaling in vivo via Tankyrase inhibition. Emma Schatoff, Weill Cornell Medicine, New York, NY, United States.

B33 CRISPR/Cas9 generation of Ret and Ntrk1 fusion oncogenes and novel in vitro sgRNA screening method. Laura Schubert, University of Colorado, Aurora, CO, United States.

B34 Evolutionary history of small cell lung cancer transformed from EGFR-mutant lung adenocarcinoma. Jeonghwan Youk, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea, Republic Of.

B35 An innovative in-vivo model of metastasizing prostate cancer using orthotopic xenografts. Johannes Linxweiler, Department of Urology, Saarland University, Homburg Saar, Germany.

B36 Novel immunodeficient rat models capable of supporting the growth of human tumor xenografts. Fallon Noto, Hera BioLabs, Lexington, KY, United States.


B38 In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Jatin Roper, Koch Institute for Integrative Cancer Research at MIT, Boston, MA, United States.


B40 Model liver cancer metastasis using 3D spheroids derived from primary tumors in liver cancer genetic mouse models. Liqin Zhu, St. Jude Children's Research Hospital, Memphis, TN, United States.

B41 Tumor endothelial cells as a targetable gateway that modulates access of drugs to cancer cells. Michael Greene, Roswell Park Cancer Institute, Buffalo, NY, United States.

B42 Targeting cancer cell CCR2 enhances synergistic immune surveillance in breast cancer. Xue-Yan He, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States.

B44 Lysyl oxidases suppress pancreatic cancer progression and inhibit FAK and ERK signaling. Mario Shields, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States.

B45, PR09 Clonal dynamics during breast cancer dormancy and recurrence. James Alvarez, Duke University, Durham, NC, United States.

B46 Varying the inoculation site of mouse syngeneic tumors can result in aberrant inclusion of lymph node tissue at tumor harvest. Renee Clift, Halozyme Therapeutics, San Diego, CA, United States.

B47 Modeling epithelial plasticity-induced erlotinib resistance in non-small cell lung cancer. Hailun Wang, Johns Hopkins University, School of Medicine, Baltimore, MD, United States.

B48 Animal models in use by the NCI PREVENT Cancer Preclinical Drug Development Program. Altaf Mohammed, National Cancer Institute, Bethesda, MD, United States.

B49 Novel epidermal growth factor receptor inhibitors cross the blood-brain barrier and inhibit the growth of metastatic non-small cell lung cancer. Nicholas Cacalano, University of California at Los Angeles, Los Angeles, CA, United States.

B50 Mouse Tumor Biology (MTB) database – An integrated data resource for GEM, inbred strains, and PDX models of human cancer. Debra Krupke, The Jackson Laboratory, Bar Harbor, ME, United States.

B51 FOXO1 determines Non-Hodgkin lymphomas reponse to anti-CD20-based therapy. Abdessamad Zerrouqi, Medical University of Warsaw, Warsaw, Masovieckie, Poland.

B52 Brusatol inhibits oral squamous cell carcinoma cells by targeting glycolytic metabolism. Xinyan Zhang, Beijing Stomatological Hospital & School of Stomatology, Capital Medical University, Beijing, China.